{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of September 2023): Yes"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/90964"],"location":["China"],"study_start_month":["9"],"keyword":["Thymalfasin","Neoadjuvant Therapy","Programmed Cell Death 1 Receptor"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer","description":"It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.","dates":{"creation":"2023-09-15"},"accession":"90964","cross_references":{"ClinicalTrials___gov":["NCT06024356"]}}